The Accuracy of Survival Time Prediction for Patients with Glioma is Improved by Measuring Mitotic Spindle Checkpoint Gene Expression

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Oct 25

PMID 22022424

Citations 38

Authors

Li Bie

Gang Zhao

Pui Cheng

Gaelle Rondeau

Steffen Porwollik

Yan Ju

Xiao-Qin Xia

Michael McClelland

Affiliations

Soon will be listed here.

Abstract

Identification of gene expression changes that improve prediction of survival time across all glioma grades would be clinically useful. Four Affymetrix GeneChip datasets from the literature, containing data from 771 glioma samples representing all WHO grades and eight normal brain samples, were used in an ANOVA model to screen for transcript changes that correlated with grade. Observations were confirmed and extended using qPCR assays on RNA derived from 38 additional glioma samples and eight normal samples for which survival data were available. RNA levels of eight major mitotic spindle assembly checkpoint (SAC) genes (BUB1, BUB1B, BUB3, CENPE, MAD1L1, MAD2L1, CDC20, TTK) significantly correlated with glioma grade and six also significantly correlated with survival time. In particular, the level of BUB1B expression was highly correlated with survival time (p<0.0001), and significantly outperformed all other measured parameters, including two standards; WHO grade and MIB-1 (Ki-67) labeling index. Measurement of the expression levels of a small set of SAC genes may complement histological grade and other clinical parameters for predicting survival time.

Citing Articles

Centromeres in cancer: Unraveling the link between chromosomal instability and tumorigenesis.

Karami Fath M, Nazari A, Parsania N, Behboodi P, Ketabi S, Razmjouei P Med Oncol. 2024; 41(11):254.

PMID: 39352464 DOI: 10.1007/s12032-024-02524-0.

Expression of the checkpoint kinase BUB1 is a predictor of response to cancer therapies.

Ciciro Y, Ragusa D, Sala A Sci Rep. 2024; 14(1):4461.

PMID: 38396175 PMC: 10891059. DOI: 10.1038/s41598-024-55080-y.

Prediction of Adrenocortical Carcinoma Relapse and Prognosis with a Set of Novel Multigene Panels.

Lin X, Gu Y, Su Y, Dong Y, Major P, Kapoor A Cancers (Basel). 2022; 14(11).

PMID: 35681785 PMC: 9179637. DOI: 10.3390/cancers14112805.

Research progress of Bub3 gene in malignant tumors.

Wang C, Cheng D, Pan C, Wang C, Nie Z Cell Biol Int. 2021; 46(5):673-682.

PMID: 34882895 PMC: 9303375. DOI: 10.1002/cbin.11740.

Inhibiting microcephaly genes as alternative to microtubule targeting agents to treat brain tumors.

Iegiani G, Di Cunto F, Pallavicini G Cell Death Dis. 2021; 12(11):956.

PMID: 34663805 PMC: 8523548. DOI: 10.1038/s41419-021-04259-6.

References

Gravendeel L, Kouwenhoven M, Gevaert O, de Rooi J, Stubbs A, Duijm J . Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009; 69(23):9065-72. DOI: 10.1158/0008-5472.CAN-09-2307. View

Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Nakamura Y, Matsuda K . CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene. 2007; 27(11):1562-71. DOI: 10.1038/sj.onc.1210799. View

Xia X, McClelland M, Porwollik S, Song W, Cong X, Wang Y . WebArrayDB: cross-platform microarray data analysis and public data repository. Bioinformatics. 2009; 25(18):2425-9. PMC: 2735672. DOI: 10.1093/bioinformatics/btp430. View

Yerushalmi R, Woods R, Ravdin P, Hayes M, Gelmon K . Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010; 11(2):174-83. DOI: 10.1016/S1470-2045(09)70262-1. View

Tran B, Rosenthal M . Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci. 2010; 17(4):417-21. DOI: 10.1016/j.jocn.2009.09.004. View

Yoshida Y, Nakada M, Harada T, Tanaka S, Furuta T, Hayashi Y . The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. J Neurooncol. 2009; 98(1):41-7. DOI: 10.1007/s11060-009-0064-5. View

Gerstner E, Yip S, Wang D, Louis D, Iafrate A, Batchelor T . Mgmt methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma. Neurology. 2009; 73(18):1509-10. PMC: 2779003. DOI: 10.1212/WNL.0b013e3181bf9907. View

Torp S, Alsaker M . Ki-67 immunoreactivity, basic fibroblastic growth factor (bFGF) expression, and microvessel density as supplementary prognostic tools in low-grade astrocytomas. An immunohistochemical study with special reference to the reliability of different.... Pathol Res Pract. 2002; 198(4):261-5. DOI: 10.1078/0344-0338-00252. View

Reis R, Nakamura M, MASUOKA J, Watanabe T, Colella S, Yonekawa Y . Mutation analysis of hBUB1, hBUBR1 and hBUB3 genes in glioblastomas. Acta Neuropathol. 2001; 101(4):297-304. DOI: 10.1007/s004010100366. View

10.

Valente V, Teixeira S, Neder L, Okamoto O, Oba-Shinjo S, Marie S . Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR. BMC Mol Biol. 2009; 10:17. PMC: 2661085. DOI: 10.1186/1471-2199-10-17. View

11.

Yamamoto Y, Matsuyama H, Chochi Y, Okuda M, Kawauchi S, Inoue R . Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer. Cancer Genet Cytogenet. 2007; 174(1):42-7. DOI: 10.1016/j.cancergencyto.2006.11.012. View

12.

Kanehisa M . The KEGG database. Novartis Found Symp. 2003; 247:91-101; discussion 101-3, 119-28, 244-52. View

13.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S . The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007; 11(45):iii-iv, ix-221. DOI: 10.3310/hta11450. View

14.

Rousseau A, Mokhtari K, Duyckaerts C . The 2007 WHO classification of tumors of the central nervous system - what has changed?. Curr Opin Neurol. 2008; 21(6):720-7. DOI: 10.1097/WCO.0b013e328312c3a7. View

15.

Gladson C, Prayson R, Liu W . The pathobiology of glioma tumors. Annu Rev Pathol. 2009; 5:33-50. PMC: 2887670. DOI: 10.1146/annurev-pathol-121808-102109. View

16.

Xu L, Niesen M, Blanck G . Linkage of a tumor immune function and cell cycle de-regulation via a gene regulatory network subcircuit. Mol Immunol. 2008; 46(4):569-75. DOI: 10.1016/j.molimm.2008.07.035. View

17.

Shichiri M, Yoshinaga K, Hisatomi H, Sugihara K, Hirata Y . Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res. 2002; 62(1):13-7. View

18.

Freije W, Castro-Vargas F, Fang Z, Horvath S, Cloughesy T, Liau L . Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004; 64(18):6503-10. DOI: 10.1158/0008-5472.CAN-04-0452. View

19.

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

20.

Weaver B, Silk A, Montagna C, Verdier-Pinard P, Cleveland D . Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell. 2006; 11(1):25-36. DOI: 10.1016/j.ccr.2006.12.003. View